Next Article in Journal
In Vivo Predictive Dissolution and Biopharmaceutic-Based In Silico Model to Explain Bioequivalence Results of Valsartan, a Biopharmaceutics Classification System Class IV Drug
Previous Article in Journal
Exploring Variability in Rifampicin Plasma Exposure and Development of Anti-Tuberculosis Drug-Induced Liver Injury among Patients with Pulmonary Tuberculosis from the Pharmacogenetic Perspective
 
 
Article

Article Versions Notes

Pharmaceutics 2024, 16(3), 389; https://doi.org/10.3390/pharmaceutics16030389
Action Date Notes Link
article xml file uploaded 12 March 2024 12:34 CET Original file -
article xml uploaded. 12 March 2024 12:34 CET Update https://www.mdpi.com/1999-4923/16/3/389/xml
article pdf uploaded. 12 March 2024 12:34 CET Version of Record https://www.mdpi.com/1999-4923/16/3/389/pdf
article html file updated 12 March 2024 12:35 CET Original file https://www.mdpi.com/1999-4923/16/3/389/html
Back to TopTop